• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

The top 10 bio­phar­ma CROs in the world—mid-2017 edi­tion

8 years ago
Deals
Outsourcing

Feds scoop up a band of biotech in­sid­ers who al­leged­ly bagged a wind­fall, and now crim­i­nal charges

8 years ago
Pharma

No­var­tis, UCSF re­searchers urge FDA to clean up its messy ad­verse events data­base

8 years ago
Pharma

UK gov­ern­ment backs $189M ef­fort to bol­ster life sci; Bay­er files he­mo­phil­ia drug; Akcea files volane­sors­en NDA

8 years ago
News Briefing

SteadyMed shares slammed as FDA toss­es its NDA for PAH drug-de­vice

8 years ago
Pharma

Dai­ichi Sankyo punts $650M col­lab­o­ra­tion pact as Charleston Labs preps a come­back at­tempt on spurned pain drug

8 years ago
R&D
Pharma

Top FDA tri­al ex­pert Richard Mosci­c­ki jumps to a se­nior post at PhRMA

8 years ago
People

In­cyte's good week con­tin­ues with an en­cour­ag­ing up­date on IDO1 star epaca­do­stat

8 years ago
R&D

Dai­ichi Sankyo dous­es a puz­zling re­port about an As­traZeneca buy­out of­fer

8 years ago
Deals

FDA ush­ers in a new era in can­cer treat­ment with 'his­toric' CAR-T ap­proval for No­var­tis

8 years ago
Pharma

Io­n­is earns $40M on Spin­raza ad­vance; Five Prime ax­es In­hi­brx deal

8 years ago
News Briefing

Star team qui­et­ly rais­es $21M to launch the lat­est im­muno-on­col­o­gy start­up Torque

8 years ago
Financing

Bio­Marin says the FDA game clock now tick­ing on their block­buster hope­ful peg­valiase

8 years ago
Pharma

Oton­o­my stag­gered by an ug­ly PhI­II fail­ure for lead pipeline drug

8 years ago
R&D

In stun­ning about-face, FDA in­vites Eli Lil­ly to quick­ly re­file block­buster hope­ful baric­i­tinib

8 years ago
Pharma

Med­i­cines Co scores FDA OK for new an­tibi­ot­ic, now up on the auc­tion block

8 years ago
R&D
Pharma

A non­prof­it group’s Cha­gas drug beat out Mar­tin Shkre­li's old ri­val to FDA OK, valu­able PRV

8 years ago
Pharma

Cel­gene antes up $195M more to stay close to For­ma, adding neu­rode­gen­er­a­tion fo­cus

8 years ago
Pharma

Cel­gene, Google dou­ble down on Ar­mo’s PhI­II im­muno-on­col­o­gy drug with $67M round

8 years ago
Financing

Dai­ichi Sankyo gets a “break­through” at the FDA; In­Vi­vo re­struc­tures, cuts jobs

8 years ago
News Briefing

Sev­en years in the mak­ing, Seat­tle Ge­net­ics picks up ear­ly op­tion on Gen­mab's ADC ef­fort

8 years ago
Pharma

FDA de­rails Acor­da's mar­ket­ing pitch, cre­at­ing a cri­sis as flag­ship drug founders

8 years ago
Pharma

Jazz gam­bles $175M on a triple-pronged armed an­ti­body pact with Im­muno­Gen

8 years ago
Pharma

As­traZeneca auc­tions off rights to an­oth­er pipeline drug as Take­da grabs $400M Parkin­son's deal

8 years ago
Pharma
First page Previous page 1090109110921093109410951096 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times